Staying ahead of the technology curve means strengthening your competitive advantage. That is why we give you data-driven innovation insights into the BioTech sector. This time, you get to discover 5 hand-picked startups developing proteomics solutions.
Global Startup Heat Map: 5 Top Proteomics Solutions
The 5 BioTech startups you will explore below are chosen based on our data-driven startup scouting approach, taking into account factors such as location, founding year, and relevance of technology, among others. This analysis is based on the Big Data & Artificial Intelligence (AI)-powered StartUs Insights Discovery Platform, covering over 1.3 million startups & scaleups globally.
The Global Startup Heat Map below highlights the 5 startups & scaleups our Innovation Researchers curated for this report. Moreover, you get insights into regions that observe a high startup activity and the global geographic distribution of the 292 companies we analyzed for this specific topic.
Click to download
Seer – Large-Scale Proteomics
Proteomics provides deep insights into the state of any organism, far surpassing genomic information. However, unlike the genome that largely is the same across cells, the proteome differs considerably depending on the cell type and time. This makes accurate quantification of the proteome incredibly difficult. That is why BioTech startups are working on a range of hardware and software solutions to tap into the benefits of large-scale proteomics.
Seer is a US-based startup that provides solutions for rapid, large-scale proteomics. The startup’s scalable technology provides unbiased coverage and deep access into the proteome, including for complex samples such as plasma and serum. Using engineered nanoparticles, Seer’s technology enables reproducible and selective binding of proteins for quantitative analysis. The startup’s solutions help companies to stratify patients based on proteomic data as well as to develop better markers.
Fastbase Solutions – Functional Diagnostics
Biomarkers enable the identification of patients that are likely to benefit from a particular therapeutic intervention. Current methods mostly compare gene expression before and after the treatment to check the response. This doesn’t take into account the complexity of subcellular pathways. Startups are developing functional diagnostics solutions based on proteomics to provide precision medicine.
Spanish startup Fastbase Solutions leverages proteomics to develop functional diagnostics. QF-Pro, the startup’s biomarker platform, provides a molecular readout of the interaction between T-cells and antigen-presenting cells. This enables healthcare professionals to determine which patients will respond to immunotherapy. The platform also helps pharma and BioTech companies to develop functional proteomic biomarkers for other use cases.
Captor Therapeutics – Undruggable Proteome
A large number of human proteins are inaccessible for current drugs and are collectively called the “undruggable proteome”. For these proteins, the binding sites are often not known. Many of these undruggable proteins also play a role in disease development, prompting pharma and BioTech startups to develop solutions that target them. Proteomics-based technologies and other emerging drug discovery solutions discover drugs that act via methods other than binding to the target protein.
Captor Therapeutics is a Polish BioTech startup targeting the undruggable proteome. Obteron, the startup’s proprietary platform, discovers therapeutic compounds. The biopharmaceutical candidates target the degradation of specific proteins via the proteasome or the autophagosome. The startup’s drug development activities target autoimmune, inflammatory, and neurodegenerative diseases.
Nplex – Protein Profiling
Traditional techniques for sequencing and quantifying proteins are difficult to scale. Moreover, they often miss out on isoforms and post-translational modifications. As a result, researchers often probe only a few proteins at a time. BioTech startups provide new protein profiling methods that help scale proteomics. Along with improved assays, these solutions often integrate machine learning algorithms.
Canadian startup nplex offers a high-throughput proteomics platform for population-wide protein profiling. The startup develops nELISA, a miniaturized and parallelized version of the enzyme-linked immunoassay (ELISA). The startup’s solution retains the sensitivity and specificity of ELISA while providing scalability to measure 120 secreted proteins at once. The solution serves BioTech companies working on clinical diagnostics, engineered stem cells, and phenotypic screening.
Evosep – Clinical Proteomics
Advancements in proteomics allow robust profiling of a large number of clinical samples, particularly for immuno-oncology. BioTech startups and scaleups are working on solutions to make proteomics technologies further standardized and high-throughput. These solutions detect post-translational modifications on proteins, as well as enable metalloproteomics and pharmacoproteomics.
Evosep is a Danish startup providing robust and fast solutions for clinical proteomics. The Evosep One Platform makes proteomics highly reproducible across runs, columns, and instruments. It increases the speed, sensitivity, and robustness of clinical proteomics. The platform also finds applications in comprehensive proteome analysis and ultra-high throughput single-shot analysis.
Discover more BioTech startups
To keep you up-to-date on the latest technology and emerging solutions, we provide you with actionable innovation intelligence – quickly and exhaustively. You can download our free Industry Innovation Reports and discover new business opportunities or save your time & let us look into your areas of interest. We provide you with an exhaustive overview of new startups, scaleups & emerging technologies that matter to you.
